Navigation Links
Gene therapy a step closer to mass production
Date:6/24/2010

EUREKA project E! 3371 Gene Transfer Agents has made great advances in the development of novel non-viral carriers able to introduce genetic material into the target cells. These new agents, derivatives of cationic amphiphilic 1,4-dihydropyridine (1,4-DHP), avoid the problems of the recipient's immune system reacting against a viral carrier. The project partners have developed methods to produce them in large amounts, which solves another of the problems with viral delivery. But the greatest advantage is that the new compounds are significantly more effective at delivering DNA into cell nuclei than other standard synthetic carriers; increasing the chance of the DNA successfully controlling the defective genes, and the disease.

Gene therapy involves the insertion of DNA into human cells within the body to treat disease. The technique is still in its early days, and has been demonstrated successfully only in the last decade. Most investigation has been into the possibilities for treating hereditary diseases related to a genetic defect, and the technique also has potential uses in treating the early stages of cancer, and in cardiovascular and neurodegenerative diseases.

Gene therapy faces many difficulties as a practical method; not the least of which is that DNA is a large and complicated structure which needs to be delivered and attached to the correct section of the recipient's set of DNA. A number of methods are in use or under investigation for introducing DNA into cells (a process known as transfection) using viruses, chemical agents or physical injection.

Viruses or chemical carriers

With viral carriers, the DNA to be introduced is injected into the virus, which carries it into the cell by way of a vesicle formed around the virus particle by the cell wall. Once inside the cell, the vesicle breaks down and the virus injects the DNA into the cell's nucleus. The viral route does, however, have major disadvanta
'/>"/>

Contact: Piotr Pogorzelski
piotr.pogorzelski@eurekanetwork.org
322-777-0979
EUREKA
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
2. McGill team discovers a piece of the puzzle for individualized cancer therapy via gene silencing
3. Making personalized lung cancer therapy a reality in Europe
4. Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer
5. 4-D software helps adjust for breathing when treating lung cancer with radiotherapy
6. Tool allows precise targeting of radiotherapy for cancer radiation therapy
7. Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say
8. Smoking during radiation therapy for head and neck cancers linked to poorer outcomes
9. JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes
10. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
11. Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy a step closer to mass production
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
(Date:11/2/2014)... child, it was fascinating to put a flashlight up ... the hand. Washington University in St. Louis engineers are ... body,s tissues to improve imaging of cancerous tissues and ... the Gene K. Beare Distinguished Professor of Biomedical Engineering ... applying a novel time-reversal technology that allows researchers to ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... signals in response to vibrations within the inner ear, could ... One way to do this could be with gene therapy ... at Emory University School of Medicine have shown that introducing ... can induce the formation of extra sensory hair cells. ...
... , This press release is available in ... (KIT) will be granted more,autonomy and far more freedom ... KIT Further Development,Act, as a result of which KIT ... its employees in the future. In,addition, KIT will have ...
... work of a Marshall University biology professor, the nation,s ... West Virginia will be preserved for future generations. ... grant from the National Science Foundation to re-curate and ... housed in the university,s College of Science. Her colleague ...
Cached Biology News:Gene therapy for hearing loss: Potential and limitations 2More freedom of discretion for KIT 2Biology professor secures grant to save West Virginia's primary natural history collection 2
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/24/2014)...  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today provided an ... No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation et ... United States District Court for the Northern District ... On November 21, 2014 the Markman hearing ...
(Date:11/23/2014)... 2014 Apiscent Labs, a privately ... chemical ingredients to the global pharmaceutical and flavor ... new website, Apiscent.com. , The Apiscent.com homepage welcomes ... design, easy navigation, rotating images and content focused ... out. , The company’s work in ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... of chemistry in the College of Science, has been ... and engineers in the early stages of their independent ... and Engineers, or PECASE. "I am very honored ... a rich environment for accomplishing nanoscience research using state-of-the-art ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Atrium Innovations Announces Third Quarter Financial Results of 2010 2Atrium Innovations Announces Third Quarter Financial Results of 2010 3Atrium Innovations Announces Third Quarter Financial Results of 2010 4Atrium Innovations Announces Third Quarter Financial Results of 2010 5Atrium Innovations Announces Third Quarter Financial Results of 2010 6Atrium Innovations Announces Third Quarter Financial Results of 2010 7Atrium Innovations Announces Third Quarter Financial Results of 2010 8Atrium Innovations Announces Third Quarter Financial Results of 2010 9Atrium Innovations Announces Third Quarter Financial Results of 2010 10Atrium Innovations Announces Third Quarter Financial Results of 2010 11Atrium Innovations Announces Third Quarter Financial Results of 2010 12Atrium Innovations Announces Third Quarter Financial Results of 2010 13Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 2Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 3Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 4Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 5Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 6Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 7Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 8
... The IDS 25-Hydroxy Vitamin D kit ... quantitative determination of 25-hydroxyvitamin D (25-OH ... human serum or plasma. Our patented ... of solvent precipitation and centrifugation and ...
... kit is a competitive enzymeimmunoassay (EIA) for ... or rat serum or plasma. Corticosterone is ... rats and mice, and in most non-mammalian ... Most mammals produce both corticosterone and cortisol, ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: